Mylan chief assails Icahn&#39;s plan to stall King acquisition
105149
By MIKE CRISSEY, Associated Press Writer, The Associated Press. Icahn, one of the 1980s most prolific corporate raiders, bought 18.
379954
Reckson Associates Realty Corp.  said on Monday that it would postpone a shareholder meeting for the second time to give billionaire Carl Icahn and his partners more time to firm up financing for their $4.6 billion bid for the company.
84238
Mylan Laboratories Inc. MYL.N on  Friday said its board of directors remains committed to the  purchase of King Pharmaceuticals Inc. KG.N, despite news that  billionaire investor Carl Icahn won regulatory approval to buy  up to 11.9 percent of Mylan's shares.
222110
Reckson Associates Realty Corp. , a New York area office landlord, on Friday again asked a group formed by billionaire Carl Icahn and real estate magnate Harry Macklowe for additional information concerning their proposed plan to buy Reckson.
402032
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) , a maker of generic drugs, and King Pharmaceutical (KG.N: Quote, Profile, Research) on Wednesday reaffirmed their commitment
768370
Billionaire investor Carl Icahn yesterday offered to purchase Mylan Laboratories for $20 per share, part of his plan to derail the Canonsburg generic drug maker&#39;s proposed acquisition of King Pharmaceuticals.
741365
PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company.
360232
Veteran financier Carl Icahn said it was &quot;reprehensible and insulting&quot; that the board of drug maker Mylan Laboratories Inc.
180677
The pressure is on for companies hoarding enormous amounts of cash. Investor activists like Carl Icahn have been hounding cash-rich companies to put their unspent dollars to use for their shareholders.
107025
Mylan Laboratories Inc. continued to insist Monday that its $4 billion acquisition of King Pharmaceuticals Inc. was in the company&#39;s best interest, following a meeting last week with Carl Icahn, who opposes the deal.
195777
Investor Carl C. Icahn on Monday said he bought more shares of Mylan Laboratories (MYL:NYSE - news - research), while unleashing more criticism of the company&#39;s effort to acquire King Pharmaceuticals.
205093
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) on Monday said its board does not believe discussions with financier Carl Icahn&#39;s about his unsolicited proposal to buy the company are in the company&#39;s best interests.
588024
Financier Carl Icahn on Friday offered to buy the shares of generic drugmaker Mylan Laboratories  that he does not already own for &#36;4.9 billion, or &#36;20 a share, according to a government filing.
243589
NEW YORK - Why has Carl Icahn set his sights on the relatively insignificant Mylan Laboratories, a generic drug company with just $1.5 billion in sales and a $4.3 billion market cap?
581364
Here&#39;s another one for the Best Poison Pen Letters of 2004 contest. Mylan Laboratories (nyse: MYL - news - people ) Chairman Milan Puskar says Carl Icahn &quot;miscalculated&quot; with his threats to block Mylan&#39;s merger
727199
Activist investor Carl Icahn  threatened on Friday to launch a proxy battle for control of  BEA Systems Inc  if the software maker does not begin  an auction process to sell itself.
114843
-- Mylan Laboratories Inc. on Wednesday said it was unlikely to complete its &#36;3.37 billion acquisition of King Pharmaceuticals Inc. at the current price because of King's need to restate earnings.